Nonprofit generic drug manufacturer building foundation for
end-to-end quality management
BARCELONA, Spain, Aug. 22, 2023 /PRNewswire/ -- Veeva Systems
(NYSE: VEEV) today announced that Civica Rx (Civica) has adopted
Veeva Vault LIMS to optimize quality control. Vault LIMS builds on
Civica's success with Veeva Vault QMS, Veeva Vault QualityDocs, and
Veeva Vault Training and establishes a foundation for unified
lab and quality processes to support a new manufacturing
facility.
"We guarantee generic drug volumes for our partner hospitals and
health systems, so having a cloud LIMS solution is a top priority,"
said Jay Benson, chief manufacturing
and supply chain officer at Civica. "Veeva Vault LIMS will simplify
our internal manufacturing and testing while driving right first
time, lead time adherence, and visibility across the value
chain."
Civica will improve productivity and speed with a unified
quality ecosystem. Within Vault LIMS, lab professionals will be
able to reference relevant methods and specifications stored in
Vault QualityDocs and surface relevant quality events from Vault
QMS during final QC review. The unification ensures up-to-date
information and improves transparency.
"Veeva Vault LIMS will help Civica create an advanced quality
control lab with a simple and efficient user experience," said
Jason Boyd, senior director, Veeva
Vault LIMS. "We're excited to partner with Civica to help them gain
agility in delivering affordable generic medicines to
patients."
To learn how Vault LIMS optimizes the quality control lab, visit
veeva.com/eu/LIMS.
About Veeva Systems
Veeva is the global leader in
cloud software for the life sciences industry. Committed to
innovation, product excellence, and customer success, Veeva serves
more than 1,000 customers, ranging from the world's largest
biopharmaceutical companies to emerging biotechs. As a Public
Benefit Corporation, Veeva is committed to balancing the interests
of all stakeholders, including customers, employees, shareholders,
and the industries it serves. For more information,
visit veeva.com/eu.
Veeva Forward-looking Statements
This release contains
forward-looking statements regarding Veeva's products and
services and the expected results or benefits from use of
our products and services. These statements are based on
our current expectations. Actual results could differ
materially from those provided in this release and we have no
obligation to update such statements. There are numerous
risks that have the potential to negatively impact
our results, including the risks and uncertainties disclosed
in our filing on Form 10-Q for the period ended April 30, 2023, which you can
find here (a summary of risks which may impact our
business can be found on pages 37 and 38), and in our subsequent
SEC filings, which you can access at sec.gov.
Contact:
|
|
|
|
Jeremy Whittaker
|
Deivis
Mercado
|
Veeva
Systems
|
Veeva
Systems
|
+49-695-095-5486
|
925-226-8821
|
jeremy.whittaker@veeva.com
|
deivis.mercado@veeva.com
|
Logo -
https://mma.prnewswire.com/media/1488285/Veeva_Systems_Logo.jpg
View original
content:https://www.prnewswire.co.uk/news-releases/veeva-vault-lims-to-support-civica-rx-quality-control-301906293.html